CN110538311A - Pure traditional Chinese medicine composition for controlling hypertension and preparation method thereof - Google Patents
Pure traditional Chinese medicine composition for controlling hypertension and preparation method thereof Download PDFInfo
- Publication number
- CN110538311A CN110538311A CN201910767024.2A CN201910767024A CN110538311A CN 110538311 A CN110538311 A CN 110538311A CN 201910767024 A CN201910767024 A CN 201910767024A CN 110538311 A CN110538311 A CN 110538311A
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- traditional chinese
- chinese medicine
- hypertension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 81
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 58
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims description 14
- 239000000463 material Substances 0.000 claims abstract description 19
- 239000004480 active ingredient Substances 0.000 claims abstract description 15
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 239000000284 extract Substances 0.000 claims description 100
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 77
- 108010038807 Oligopeptides Proteins 0.000 claims description 32
- 102000015636 Oligopeptides Human genes 0.000 claims description 32
- 239000000706 filtrate Substances 0.000 claims description 30
- 239000000843 powder Substances 0.000 claims description 30
- 230000002829 reductive effect Effects 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 244000068988 Glycine max Species 0.000 claims description 22
- 235000010469 Glycine max Nutrition 0.000 claims description 22
- 238000000605 extraction Methods 0.000 claims description 22
- 238000001914 filtration Methods 0.000 claims description 20
- 240000006509 Gynostemma pentaphyllum Species 0.000 claims description 19
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 claims description 19
- 241000185686 Apocynum venetum Species 0.000 claims description 17
- 244000179560 Prunella vulgaris Species 0.000 claims description 17
- 235000008113 selfheal Nutrition 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 15
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims description 14
- 244000237330 gutta percha tree Species 0.000 claims description 14
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims description 12
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 claims description 12
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 claims description 12
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 claims description 12
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 claims description 12
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 claims description 12
- 229940025878 hesperidin Drugs 0.000 claims description 12
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 claims description 12
- 235000006533 astragalus Nutrition 0.000 claims description 11
- 241000045403 Astragalus propinquus Species 0.000 claims description 10
- 241000361919 Metaphire sieboldi Species 0.000 claims description 10
- 239000010404 Scutellaria baicalensis extract Substances 0.000 claims description 10
- 238000009835 boiling Methods 0.000 claims description 10
- 239000011812 mixed powder Substances 0.000 claims description 10
- 238000002791 soaking Methods 0.000 claims description 10
- 241000218236 Cannabis Species 0.000 claims description 9
- 235000011201 Ginkgo Nutrition 0.000 claims description 8
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 8
- 239000009429 Ginkgo biloba extract Substances 0.000 claims description 8
- 244000046146 Pueraria lobata Species 0.000 claims description 8
- 235000010575 Pueraria lobata Nutrition 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 6
- 244000061121 Rauvolfia serpentina Species 0.000 claims description 5
- 235000019206 astragalus extract Nutrition 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 235000020357 syrup Nutrition 0.000 claims description 5
- 239000006188 syrup Substances 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000006184 cosolvent Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 230000002335 preservative effect Effects 0.000 claims description 3
- 239000000080 wetting agent Substances 0.000 claims description 3
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 241000304195 Salvia miltiorrhiza Species 0.000 claims 2
- 244000194101 Ginkgo biloba Species 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 abstract description 53
- 230000000694 effects Effects 0.000 abstract description 46
- 230000001603 reducing effect Effects 0.000 abstract description 34
- 210000004369 blood Anatomy 0.000 abstract description 26
- 239000008280 blood Substances 0.000 abstract description 26
- 230000017531 blood circulation Effects 0.000 abstract description 9
- 210000004556 brain Anatomy 0.000 abstract description 9
- 210000005259 peripheral blood Anatomy 0.000 abstract description 9
- 239000011886 peripheral blood Substances 0.000 abstract description 9
- 208000007530 Essential hypertension Diseases 0.000 abstract description 8
- 230000001737 promoting effect Effects 0.000 abstract description 8
- 229940126673 western medicines Drugs 0.000 abstract description 6
- 230000002195 synergetic effect Effects 0.000 abstract description 5
- 235000013305 food Nutrition 0.000 abstract description 4
- 230000008506 pathogenesis Effects 0.000 abstract description 4
- 210000002784 stomach Anatomy 0.000 abstract description 4
- 208000004880 Polyuria Diseases 0.000 abstract description 3
- 230000035487 diastolic blood pressure Effects 0.000 abstract description 3
- 230000035619 diuresis Effects 0.000 abstract description 3
- 210000002385 vertebral artery Anatomy 0.000 abstract description 3
- 238000009098 adjuvant therapy Methods 0.000 abstract description 2
- 206010047163 Vasospasm Diseases 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 description 18
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- 230000006870 function Effects 0.000 description 12
- 244000132619 red sage Species 0.000 description 12
- 230000001276 controlling effect Effects 0.000 description 10
- 206010019233 Headaches Diseases 0.000 description 9
- 231100000869 headache Toxicity 0.000 description 9
- 210000004204 blood vessel Anatomy 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 208000002173 dizziness Diseases 0.000 description 8
- 241000218628 Ginkgo Species 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 235000012000 cholesterol Nutrition 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 241000208332 Rauvolfia Species 0.000 description 6
- 240000008022 Rauvolfia verticillata Species 0.000 description 6
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 6
- 206010022437 insomnia Diseases 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 240000004534 Scutellaria baicalensis Species 0.000 description 5
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 5
- 239000002220 antihypertensive agent Substances 0.000 description 5
- 208000010125 myocardial infarction Diseases 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 235000019640 taste Nutrition 0.000 description 5
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 4
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229940127088 antihypertensive drug Drugs 0.000 description 4
- MOLPUWBMSBJXER-YDGSQGCISA-N bilobalide Chemical compound O([C@H]1OC2=O)C(=O)[C@H](O)[C@@]11[C@@](C(C)(C)C)(O)C[C@H]3[C@@]21CC(=O)O3 MOLPUWBMSBJXER-YDGSQGCISA-N 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 230000001631 hypertensive effect Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 230000027939 micturition Effects 0.000 description 4
- 230000002107 myocardial effect Effects 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 201000004239 Secondary hypertension Diseases 0.000 description 3
- 208000009205 Tinnitus Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 108010028144 alpha-Glucosidases Proteins 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000001914 calming effect Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 235000021588 free fatty acids Nutrition 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 208000013403 hyperactivity Diseases 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 231100000886 tinnitus Toxicity 0.000 description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 235000008496 Drimys aromatica Nutrition 0.000 description 2
- 206010013954 Dysphoria Diseases 0.000 description 2
- 241000208688 Eucommia Species 0.000 description 2
- 240000002262 Litsea cubeba Species 0.000 description 2
- 235000012854 Litsea cubeba Nutrition 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Chemical class 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 230000004531 blood pressure lowering effect Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000001913 cellulose Chemical class 0.000 description 2
- 229920002678 cellulose Chemical class 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 2
- 235000011957 flavonols Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 208000034783 hypoesthesia Diseases 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000000893 inhibin Substances 0.000 description 2
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- -1 liquid paraffin Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229940118019 malondialdehyde Drugs 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Chemical class 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000001148 spastic effect Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000208327 Apocynaceae Species 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010005746 Blood pressure fluctuation Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 108010010803 Gelatin Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 206010010164 Hypertension complications Diseases 0.000 description 1
- 206010055171 Hypertensive nephropathy Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010028836 Neck pain Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 1
- 235000003283 Pachira macrocarpa Nutrition 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010003541 Platelet Activating Factor Proteins 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- 235000010674 Prunella vulgaris Nutrition 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- 241000207929 Scutellaria Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 240000001085 Trapa natans Species 0.000 description 1
- 235000014364 Trapa natans Nutrition 0.000 description 1
- 241000157352 Uncaria Species 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- QMNWISYXSJWHRY-YLNUDOOFSA-N astragaloside IV Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)[C@H]4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C[C@H]3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-YLNUDOOFSA-N 0.000 description 1
- QMNWISYXSJWHRY-BCBPIKMJSA-N astragaloside IV Natural products CC(C)(O)[C@@H]1CC[C@@](C)(O1)[C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@H](O)[C@@H](O)[C@H]5O)[C@H]6C(C)(C)[C@H](CC[C@@]67C[C@@]47CC[C@]23C)O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O QMNWISYXSJWHRY-BCBPIKMJSA-N 0.000 description 1
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 description 1
- 229940015301 baicalein Drugs 0.000 description 1
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 1
- 229960003321 baicalin Drugs 0.000 description 1
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000015606 cardiovascular system disease Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- PFKIBRPYVNVMRU-UHFFFAOYSA-N cyclosieversioside F Natural products CC(C)(O)C1COC(C)(C1)C2C(O)CC3(C)C4CC(OC5OC(CO)C(O)C(O)C5O)C6C(C)(C)C(CCC67CC47CCC23C)OC8OCC(O)C(O)C8O PFKIBRPYVNVMRU-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000007946 flavonol Chemical class 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Chemical class 0.000 description 1
- 229920000159 gelatin Chemical class 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000018997 giddiness Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000000260 hypercholesteremic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 208000015210 hypertensive heart disease Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229950007002 phosphocreatine Drugs 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 235000005412 red sage Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 235000009165 saligot Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/424—Gynostemma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/536—Prunella or Brunella (selfheal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a pure traditional Chinese medicine composition for controlling hypertension, which is prepared by using a pure traditional Chinese medicine formula aiming at the pathogeny and pathogenesis of the primary hypertension, is different from the traditional Chinese medicine and western medicines for adjuvant therapy, and simultaneously, the invention selects simple raw materials extracted from food, and can be suitable for any group of people; the active ingredients in the medicinal materials generate synergistic effect, and the effects of improving vertebral artery, brain blood, peripheral blood and stomach blood circulation, relieving brain and peripheral vasospasm, promoting diuresis, lowering blood pressure, and reducing diastolic pressure are mutually enhanced, so that the effect of treating primary hypertension is achieved.
Description
Technical Field
The invention relates to a traditional Chinese medicine composition and a preparation method thereof, in particular to a pure traditional Chinese medicine composition for controlling hypertension and a preparation method thereof.
background
Hypertension is a common disease, frequently encountered disease, and a risk factor for coronary heart disease, renal failure, ocular fundus disease and other diseases. With the improvement of living standard of people, the prevalence rate is on the rise in recent years, and the prevalence rate becomes an important factor threatening human health and life, and the prevention and treatment of hypertension becomes an important subject of world medicine. Therefore, the development of the health food with the effect of controlling the hypertension has great significance in production practice, and the health food can prevent the hypertension, reduce the blood pressure of a patient and improve the life quality of people through food therapy. The high recurrence rate, high disability rate and high death rate of hypertension show a trend of increasing year by year, and the harmfulness is not inferior to that of cancer at all. Hypertension patients in China reach 3.3 hundred million people, and the elderly are higher. Hypertension becomes one of the main cardiovascular and cerebrovascular diseases of the old, and seriously threatens the health of the middle-aged and the elderly. Hypertension is a clinical syndrome mainly manifested by increased arterial pressure in the systemic circulation, and is the most common cardiovascular disease. Hypertension can be divided into primary and secondary categories. In most patients, the cause of hypertension is unknown, called essential hypertension, and accounts for more than 95% of the total hypertension; in less than 5% of patients, elevated blood pressure is a clinical manifestation of certain diseases, with a clear and independent cause of disease itself, called secondary hypertension. In recent years, antihypertensive drugs have been developed rapidly, and various antihypertensive drugs can be used singly or in combination according to the characteristics of different patients. At present, the commonly used antihypertensive drugs are mainly divided into six categories, namely diuretics, calcium channel blockers, Angiotensin Converting Enzyme (ACE) inhibitors and a-blockers. Western medicines mainly adopt western medicines such as reserpine, nimodipine, betalep, apocynum venetum and the like for reducing blood pressure for many years, and although chemical medicines have quick action, the blood pressure fluctuation is large in the blood pressure reducing process, the side effect is large, and medicine dependence is easy to form. Therefore, the western medicine antihypertensive drug needs to be taken for a long time without interruption, but a plurality of Chinese herbal medicine compound preparations in China have mild antihypertensive effect and small toxic and side effect, have obvious curative effect on various hypertension diseases, and are low in price and popular with patients.
Disclosure of Invention
The invention aims to solve the defects of the technical problems and provides a pure traditional Chinese medicine composition for controlling hypertension, aiming at the pathogenesis of the primary hypertension, the mutual synergistic effect of the active ingredients of various traditional Chinese medicines is utilized, the blood pressure can be reduced by soothing liver depression, reducing liver fire, reducing stomach qi, improving brain and peripheral blood circulation, inducing diuresis and reducing blood pressure, the diastolic pressure can be reduced, and the medicines are matched together to achieve the effect of reducing blood pressure.
The invention uses a pure traditional Chinese medicine formula, is different from the traditional Chinese medicine and western medicines for adjuvant therapy, and simultaneously selects simple raw materials for food extraction, thus being suitable for any people; in addition, the active ingredients in the medicinal materials generate synergistic action, and the effects of improving the blood circulation of vertebral artery, brain blood, peripheral blood and stomach are mutually enhanced, the spastic effect of brain and peripheral blood vessels is relieved, and the aims of inducing diuresis, reducing blood pressure and reducing diastolic pressure are fulfilled, so that the effect of treating the primary hypertension is achieved.
the technical scheme of the invention is as follows:
a pure traditional Chinese medicine composition for controlling hypertension comprises the following raw materials in parts by weight: 6-12 parts of soybean oligopeptide powder, 1-3 parts of fructus cannabis oligopeptide powder, 6-8 parts of hesperidin, 3-6 parts of earthworm powder, 6-10 parts of apocynum venetum extract, 6-8 parts of rauwolfia extract, 8-12 parts of eucommia ulmoides extract, 8-14 parts of selfheal extract, 10-16 parts of astragalus membranaceus extract, 8-12 parts of radix puerariae extract, 8-12 parts of scutellaria baicalensis extract, 6-10 parts of moutan bark extract, 10-12 parts of folium ginkgo extract, 10-12 parts of gynostemma pentaphylla extract and 6-12 parts of salvia miltiorrhiza extract.
a preparation method of a traditional Chinese medicine composition for controlling hypertension comprises the following steps:
Step one, after the traditional Chinese medicine raw materials of apocynum venetum, rauvolfia verticillata, eucommia ulmoides, selfheal, astragalus mongholicus, radix puerariae, scutellaria baicalensis, cortex moutan radicis, ginkgo leaves, gynostemma pentaphylla and salvia miltiorrhiza are inspected to be qualified, and each traditional Chinese medicine is independently divided into three equal parts;
step two, putting the first part of each traditional Chinese medicine into an extraction tank, soaking for 12 hours by using 12 times of water, keeping boiling for 1-2 hours at 100 ℃, extracting for 2 times, adding 12 times of water amount corresponding to the total weight of the medicinal materials each time, combining the extracting solutions, filtering, and concentrating the filtrate under reduced pressure to obtain clear paste with the relative density of 1.05-1.25 at 70-80 ℃ to obtain the first active component of each traditional Chinese medicine;
Step three, putting the second equal part of each traditional Chinese medicine into an extraction tank, soaking for 12 hours by using 12 times of water, keeping boiling for 1-2 hours at 100 ℃, extracting for 2 times, adding 12 times of water by weight of the total weight of the medicinal materials every time, combining the extracting solutions, filtering, concentrating the filtrate under reduced pressure to obtain clear paste with the relative density of 1.10-1.20 at 70-80 ℃, cooling, adding 4 times of ethanol, fully stirring, standing and refrigerating for 12-24 hours, filtering, recovering the ethanol from the filtrate, concentrating the filtrate under reduced pressure to obtain extract with the relative density of 1.15-1.30 at 70-80 ℃, and obtaining the second active component of each traditional Chinese medicine;
Step four, carrying out reflux extraction on the third equal part of each traditional Chinese medicine for 2 times by using 40-80% ethanol, wherein the dosage of the ethanol is 4-10 times of that of the medicinal materials each time, the extraction time is 1-2 hours, combining the extracting solutions, filtering, recovering the ethanol from the filtrate, and concentrating the filtrate under reduced pressure to obtain an extract with the relative density of 1.20-1.35 at the temperature of 60-80 ℃, so as to obtain the third active ingredient of each traditional Chinese medicine;
step five, respectively taking the active ingredients of the first, second and third parts in equal parts, mixing and stirring 6-10 parts of apocynum venetum extract, 6-8 parts of rauwolfia extract, 8-12 parts of eucommia ulmoides extract, 8-14 parts of selfheal extract, 10-16 parts of astragalus extract, 8-12 parts of kudzu root extract, 8-12 parts of scutellaria baicalensis extract, 6-10 parts of moutan bark extract, 10-12 parts of ginkgo leaf extract, 10-12 parts of gynostemma pentaphylla extract and 6-12 parts of salvia miltiorrhiza extract uniformly, adding 6-12 parts of soybean oligopeptide powder, 1-3 parts of fructus cannabis oligopeptide powder, 6-8 parts of hesperidin and 3-6 parts of earthworm powder, mixing and stirring uniformly to obtain mixed powder;
And sixthly, mixing the mixed powder obtained in the fifth step with a medically acceptable carrier to prepare various common preparations, namely tablets, granules, capsules, oral liquid and syrup.
the medically acceptable carriers are: diluent, wetting agent and adhesive, disintegrating agent, lubricant, cosolvent, corrective and preservative.
diluent agent: starch, sugar powder, lactose, dextrin, microcrystalline cellulose, inorganic salt, and sugar alcohol.
Wetting agent and binder: one or more of purified water, ethanol, gelatin, polyethylene glycol and cellulose derivatives.
Disintegrating agent: one or more of starch, sodium carboxymethyl starch, cellulose derivative and crospovidone.
Lubricant: one or more of magnesium stearate, silica gel micropowder, pulvis Talci, and polyethylene glycol.
Cosolvent: one or more of water, ethanol, glycerol, propylene glycol, liquid paraffin, and vegetable oil.
Flavoring agent: one or more of sucrose, simple syrup, aromatic, Mel, glycyrrhizic acid and stevioside.
Preservative: one or more of benzoic acid, sorbic acid, propionic acid, methyl ester, ethyl ester and propyl ester.
The invention divides the traditional Chinese medicine raw materials of apocynum venetum, rauvolfia verticillata, eucommia ulmoides, selfheal, astragalus mongholicus, radix puerariae, scutellaria baicalensis, moutan bark, ginkgo leaves, gynostemma pentaphylla and salvia miltiorrhiza into three equal parts, and the three parts are independently prepared by three methods respectively, so that the traditional Chinese medicine medicinal substances are ensured to overflow to the maximum extent, and the purity, the alcohol degree and the taste are not influenced by other substances when the traditional Chinese medicine medicinal substances overflow.
The beneficial effects and advantages of the technology of the invention are as follows:
1. the composition selects soybean oligopeptide powder, fructus cannabis oligopeptide powder, hesperidin, devilpepper extract, apocynum venetum extract, eucommia bark extract, selfheal extract, astragalus extract, kudzu root extract, scutellaria baicalensis extract, moutan bark extract, ginkgo leaf extract, gynostemma pentaphylla extract, salvia miltiorrhiza extract and earthworm powder, breaks through the defects of poor effect, unstable blood pressure and more complications or aggravation of the conventional single-ingredient or multi-ingredient combined clinical treatment, and cannot fundamentally condition the internal organs of the five-organ and six-organ, balance yin and yang, improve body circulation and improve blood comprehensive conditioning and treat hypertension by simply reducing the blood pressure.
2. aiming at the pathogenesis and pathogenesis of primary hypertension and secondary hypertension, the composition with the function of reducing blood pressure mutually improves the function of improving the blood circulation of vertebral artery, brain blood, peripheral blood and stomach by utilizing the mutual synergistic action of the active ingredients of 15 Chinese herbal medicines, relieves the spastic action of brain and peripheral blood vessels, improves the blood viscosity, reduces atherosclerosis, benefits qi, activates blood, promotes qi, removes blood stasis, protects vascular endothelium, repairs vascular injury and enhances the elasticity of blood vessels. The medicines are combined together to achieve the effect of lowering blood pressure, thereby achieving the effect of treating primary hypertension and secondary hypertension, greatly relieving complications of hypertension and solving the pain of patients with hypertension caused by long-term administration.
3. the composition has the advantages of general formula, front and back treatment and proper proportion, the medicines are common products, the effects are not excessive, the effects of balancing heart, brain, liver and kidney yin and yang, tonifying qi and activating blood, relaxing tendons and activating collaterals, softening blood vessels, reducing blood fat and blood pressure, improving myocardial power, expanding and softening brain and peripheral blood vessels, improving blood circulation and immunity of the organism, effectively eliminating symptoms such as headache, dizziness, insomnia, palpitation and the like, the hypertension is clinically cured, and the diseases do not rebound after medicine withdrawal.
4. The composition for controlling the hypertension, which is prepared by the invention, has obvious curative effect on the hypertension, has the total effective rate of 96.3 percent, and is a new generation of specific therapy for integrally treating the hypertension.
the compositions of the invention are characterized in that:
The composition is prepared by combining soybean oligopeptide powder, fructus cannabis oligopeptide powder, hesperidin, devilpepper extract, apocynum venetum extract, eucommia bark extract, selfheal extract, astragalus extract, kudzu root extract, scutellaria baicalensis extract, moutan bark extract, ginkgo leaf extract, gynostemma pentaphylla extract, salvia miltiorrhiza extract and earthworm powder. The active ingredients in the medicinal materials generate synergistic effect, and mutually enhance effect, repair five internal organs, balance yin and yang, and improve body circulation, thereby achieving the effect of treating hypertension. The composition of the invention is a new generation of specific therapy for treating hypertension.
1. Soybean oligopeptide powder: peptides are intermediate substances of proteins and amino acids, and are formed by combining a plurality of amino acids. The molecular size is between protein and amino acid. The soybean oligopeptide is formed by gathering a plurality of amino acid molecules to be absorbed integrally, while the amino acids need to be absorbed one by one, and the oligopeptide can be absorbed by the human body more quickly than the amino acids. (1) Regulating blood lipid and reducing cholesterol: the soybean oligopeptide has a selective action characteristic for reducing the cholesterol of a human body, when the cholesterol of the human body is in a normal value state, the soybean oligopeptide is ingested to have no cholesterol reducing effect, after the soybean oligopeptide is ingested by a hypercholesteremic patient, the cholesterol reducing effect is generated, and the reduced lipoprotein belongs to low-density lipoprotein harmful to the human body, is beneficial to the human body, can carry blood fat molecules to the liver to decompose, and has no reducing effect on high-density lipoprotein discharged from the body. (2) The function of improving immunity is as follows: the soybean oligopeptide can improve the cellular immune function of the body, promote the proliferation of T lymphocytes, enhance the function of macrophages and enhance the activity of NK cells. If the body is uncomfortable, the soybean oligopeptide rapidly exerts immune effect when being eaten. (3) Blood pressure reduction: the soybean oligopeptide has the functions of inhibiting the activity of Angiotensin Converting Enzyme (ACE) and preventing the contraction of the peripheral blood vessels, so the blood pressure reducing effect is obvious. The soybean oligopeptide has no influence on normal blood pressure people, is safe and reliable, can keep the original normal blood pressure unchanged after being taken, and does not produce the effect of reducing blood pressure. But can make the blood pressure reach normal level for the hypertensive. The soybean oligopeptide has stable blood pressure reducing effect, does not generate large fluctuation in the process of reducing blood pressure by medicaments, does not have the side effect that the blood pressure of the medicaments is reduced to harm other organs such as liver, kidney and the like, and particularly has more remarkable effect on patients with primary hypertension. (4) Buffering blood sugar rise: the soybean oligopeptide is an effective component for forming alpha-glucosidase inhibin. The alpha glucosidase inhibin formed by soybean oligopeptide has the functions of preventing and delaying the degradation of carbohydrates such as starch, sucrose, oligosaccharide and the like by alpha-glucosidase, and relieving the phenomenon that the carbohydrates are converted into glucose and enter blood to cause the rise of blood sugar, thereby achieving the purpose of lowering the blood sugar index and preventing complications caused by the rise of blood sugar in the blood. (5) Oxidation resistance and aging delay: the soybean oligopeptide can improve the activity of superoxide dismutase and glutathione peroxidase, inhibit lipid peroxidation, remove hydroxyl free radical, reduce tissue oxidation, and protect organism.
2. hesperidin: hesperidin is a flavonoid substance widely existing in citrus fruits, and the crude product obtained by extraction is light yellow powder. Hesperidin has effects of maintaining osmotic pressure, enhancing capillary toughness, shortening bleeding time, reducing cholesterol, etc., is clinically used for auxiliary treatment of cardiovascular system diseases, can be used for cultivating various medicines for preventing arteriosclerosis and myocardial infarction, and is one of main raw materials of adult medicine "Maitong".
3. Earthworm: salty and cold in nature, calming wind, clearing heat, activating collaterals, relieving asthma, promoting urination and lowering blood pressure. Has obvious blood pressure lowering effect on liver yang hyperactivity type hypertension.
4. Devilpepper extract: alias: mountain pepper, mountain water chestnut, mountain pepper and rauvolfia verticillata. Is root of Rauwolfia root of Apocynaceae, bitter and slightly pungent, and cool in nature. Has effects of clearing heat, lowering blood pressure, and tranquilizing mind. Can be used for treating common cold, fever, headache, body pain, sore throat, hypertension, vertigo, and insomnia. The functions are as follows: clear heat, lower blood pressure, tranquilize mind. The traditional Chinese medicine is mainly used for treating cold, fever, headache, body pain, sore throat, hypertension, dizziness and insomnia.
5. the apocynum venetum extract is used for calming the liver and reducing the blood pressure. The tea has light taste and cool property, calms the liver, relieves wind, clears heat, has the effects of calming the liver, reducing blood pressure, clearing heat and promoting urination, is commonly used for liver yang hyperactivity or liver heat type hypertension, and has good effects on patients with dizziness, headache, fullness in the head, dysphoria and insomnia. Apocynum venetum is the most commonly used traditional Chinese medicine for treating hypertension in traditional Chinese medicine.
6. Eucommia ulmoides extract for lowering blood pressure. Has sweet and warm nature and taste, has the efficacies of nourishing liver and kidney, strengthening bones and muscles, preventing miscarriage and reducing blood pressure, can reduce blood pressure by being combined with abalone shell, selfheal, white paeony root and the like, and has no cold and cool disadvantages for reducing blood pressure of people with physical weakness. Has bidirectional regulation effect on blood pressure, and Eucommiae cortex contains various unsaturated fatty acids, and can help hypertension patients to prevent various cardiovascular and cerebrovascular diseases such as complicated myocardial infarction. Eucommia ulmoides is also commonly used as a traditional Chinese medicine for treating hypertension.
7. The selfheal extract is used for clearing away fire and reducing blood pressure. Cold in nature, pungent and bitter in flavor. Clearing liver fire, eliminating stagnation, eliminating phlegm, and lowering blood pressure. Because of its good action of clearing liver fire, it is indicated for hypertension with liver heat and yang hyperactivity. The prunella vulgaris extract has an antagonistic effect on vasoconstriction caused by norepinephrine, can relax blood vessels, and has a remarkable and lasting blood pressure reducing effect. It is often used to treat hypertension with syndrome of liver heat such as headache, blurred vision, tinnitus, dysphoria with smothery sensation, and insomnia.
8. Astragalus extract: mild in nature and sweet in taste, and has the effects of invigorating qi, consolidating superficial resistance, benefiting qi, nourishing blood, promoting urination, expelling toxin, expelling pus and promoting granulation. Pharmacological research shows that astragalus has the effects of strengthening myocardial contraction force, relaxing coronary vessels, reducing blood pressure, protecting liver cells and reducing blood sugar. Is very suitable for patients with hypertension due to deficiency of both qi and blood, and the Y-aminobutyric acid and astragaloside IV in radix astragali have the function of bidirectionally regulating blood pressure.
9. radix Puerariae extract for dilating blood vessel and lowering blood pressure. Sweet, pungent and cool in nature, is a commonly used wind-dispelling and exterior-syndrome-relieving medicine, and can dilate coronary vessels and cerebral vessels and increase coronary blood flow and cerebral blood flow. The kudzu root can directly dilate blood vessels, so that the peripheral resistance is reduced, and the blood pressure is obviously reduced. The clinical report shows that the traditional Chinese medicine composition has obvious curative effect on treating hypertension accompanied with neck pain. It is often combined with hooked uncaria to treat hypertension, and has obvious effect of lowering blood pressure and good effect on headache, dizziness, numbness of limbs, tinnitus and other symptoms caused by hypertension.
10. The scutellaria baicalensis extract has the functions of promoting blood circulation and reducing blood pressure. Bitter and cold taste, clearing heat and drying dampness, purging fire and removing toxicity, and has the function of eliminating symptoms such as dizziness, headache, oral bitterness, vexation and the like for the hypertension with excessive heat in liver channel. Mainly contains baicalein, baicalin, etc., and has effects of clearing heat and purging pathogenic fire. Modern pharmacological research finds that the scutellaria has the effects of reducing blood pressure, promoting urination, relieving fever, tranquilizing, benefiting gallbladder and the like. It can be made into decoction or infusion, and has obvious effect of lowering blood pressure, and can be used for treating hypertension.
11. Moutan bark extract has effect in lowering blood pressure. The moutan bark is a very rare medicinal material and has obvious blood pressure lowering effect after being decocted with water. However, the medicine is also contraindicated in the taking process, and needs to be noticed, for example, patients with cold body and blood deficiency are not suitable for taking the medicine, and the medicine is also taken carefully in menstrual period and pregnant women.
12. Ginkgo leaf extract: has effects of promoting blood circulation, removing blood stasis, astringing lung, relieving asthma, resisting aging, and enhancing immunity. Can be used for treating blood stasis, obstruction of collaterals, thoracic obstruction, cardialgia, apoplexy, hemiplegia, cough with asthma due to lung deficiency, and hyperlipidemia. The most important extracts of ginkgo leaf are bilobalide and flavonol, and the bilobalide has the function of resisting platelet activating factor and can improve blood circulation: flavonols can dilate blood vessels, scavenge free radicals, prevent arteriosclerosis, etc. Can lower blood pressure by increasing vascular permeability and elasticity, and has good effect of lowering blood pressure.
13. The gynostemma pentaphylla extract: the gynostemma pentaphylla has the effect of (1) treating hyperlipidemia, hypertension and hyperglycemia, has remarkable curative effect on hyperlipidemia in particular, and is difficult to replace other medicines and foods. (2) Gynostemma pentaphyllum has effects of remarkably reducing cholesterol (TCH), Triglyceride (TG), Low Density Lipoprotein (LDL), increasing High Density Lipoprotein (HDL), protecting blood vessel wall cells, preventing lipid deposition on blood vessel wall, and resisting arteriosclerosis. (3) The gynostemma pentaphylla has the functions of obviously reducing blood viscosity and regulating blood pressure, can prevent microthrombosis and increase the tolerance of myocardial cells to oxygen deficiency, and plays a role in protecting the myocardium. (4) The gynostemma pentaphylla extract has obvious protective effect on experimental myocardial infarction: can reduce myocardial infarction range, inhibit Free Fatty Acid (FFA) increase after myocardial infarction, reduce Malondialdehyde (MDA) content, protect myocardial SOD and phosphocreatine kinase (CPK) activity, and correct metabolism disorder of FFA during myocardial ischemia.
14. The red sage root extract: has mild nature and bitter taste, has obvious effects of dilating peripheral blood vessels and lowering blood pressure, is suitable for patients with hypertension of blood stasis and collaterals obstruction type and qi and blood deficiency type, and can relieve symptoms such as dizziness and headache.
The suitable population is as follows:
1. The hypertension patients who take various western medicine antihypertensives for a long time and have liver and kidney damage and unstable blood pressure for a long time, and the hypertension patients who have drug resistance to various western medicines and have poor combined application effect of various medicines.
2. the blood pressure is easy to rebound when the patient is tired, stays up all night and fluctuates, and the patient refuses the toxic and side effect of western medicines. The blood pressure is normally 140mmHg at high pressure and 100mmHg at low pressure, and is critical hypertension.
3. the health food is fat, high in oil and salt in the diet, and has symptoms of dizziness, headache, tinnitus, giddiness, insomnia, numbness of limbs, renal hypofunction, etc. after smoking or drinking.
4. The blood pressure is better controlled, but hypertensive patients with or without obvious hypertension complications such as hypertensive heart disease, cerebral apoplexy, hypertensive eye disease, hypertensive nephropathy, hypertensive diabetes and the like already appear.
Detailed Description
The present invention will be described in detail with reference to examples.
Example 1
A preparation method of a traditional Chinese medicine composition for controlling hypertension comprises the following steps:
Step one, after the traditional Chinese medicine raw materials of apocynum venetum, rauvolfia verticillata, eucommia ulmoides, selfheal, astragalus mongholicus, radix puerariae, scutellaria baicalensis, cortex moutan radicis, ginkgo leaves, gynostemma pentaphylla and salvia miltiorrhiza are inspected to be qualified, and each traditional Chinese medicine is independently divided into three equal parts;
Step two, putting the first part of each traditional Chinese medicine into an extraction tank, soaking for 12 hours by using 12 times of water, keeping boiling for 1-2 hours at 100 ℃, extracting for 2 times, adding 12 times of water amount corresponding to the total weight of the medicinal materials each time, combining the extracting solutions, filtering, and concentrating the filtrate under reduced pressure to obtain clear paste with the relative density of 1.05-1.25 at 70-80 ℃ to obtain the first active component of each traditional Chinese medicine;
Step three, putting the second equal part of each traditional Chinese medicine into an extraction tank, soaking for 12 hours by using 12 times of water, keeping boiling for 1-2 hours at 100 ℃, extracting for 2 times, adding 12 times of water by weight of the total weight of the medicinal materials every time, combining the extracting solutions, filtering, concentrating the filtrate under reduced pressure to obtain clear paste with the relative density of 1.10-1.20 at 70-80 ℃, cooling, adding 4 times of ethanol, fully stirring, standing and refrigerating for 12-24 hours, filtering, recovering the ethanol from the filtrate, concentrating the filtrate under reduced pressure to obtain extract with the relative density of 1.15-1.30 at 70-80 ℃, and obtaining the second active component of each traditional Chinese medicine;
Step four, carrying out reflux extraction on the third equal part of each traditional Chinese medicine for 2 times by using 40-80% ethanol, wherein the dosage of the ethanol is 4-10 times of that of the medicinal materials each time, the extraction time is 1-2 hours, combining the extracting solutions, filtering, recovering the ethanol from the filtrate, and concentrating the filtrate under reduced pressure to obtain an extract with the relative density of 1.20-1.35 at the temperature of 60-80 ℃, so as to obtain the third active ingredient of each traditional Chinese medicine;
Step five, respectively taking the active ingredients of the first part, the second part and the third part, mixing and stirring 6 parts of apocynum venetum extract, 8 parts of rauwolfia extract, 12 parts of eucommia ulmoides extract, 8 parts of selfheal extract, 16 parts of astragalus membranaceus extract, 8 parts of kudzu root extract, 12 parts of scutellaria baicalensis extract, 6 parts of moutan bark extract, 12 parts of ginkgo leaf extract, 12 parts of gynostemma pentaphylla extract and 6 parts of salvia miltiorrhiza extract uniformly, adding 6 parts of soybean oligopeptide powder, 1 part of fructus cannabis oligopeptide powder, 8 parts of hesperidin and 6 parts of earthworm powder, mixing and stirring uniformly to obtain mixed powder;
and sixthly, mixing the mixed powder obtained in the fifth step with a medically acceptable carrier to prepare various common preparations, namely tablets, granules, capsules, oral liquid and syrup.
Example 2
A preparation method of a traditional Chinese medicine composition for controlling hypertension comprises the following steps:
step one, after the traditional Chinese medicine raw materials of apocynum venetum, rauvolfia verticillata, eucommia ulmoides, selfheal, astragalus mongholicus, radix puerariae, scutellaria baicalensis, cortex moutan radicis, ginkgo leaves, gynostemma pentaphylla and salvia miltiorrhiza are inspected to be qualified, and each traditional Chinese medicine is independently divided into three equal parts;
Step two, putting the first part of each traditional Chinese medicine into an extraction tank, soaking for 12 hours by using 12 times of water, keeping boiling for 1-2 hours at 100 ℃, extracting for 2 times, adding 12 times of water amount corresponding to the total weight of the medicinal materials each time, combining the extracting solutions, filtering, and concentrating the filtrate under reduced pressure to obtain clear paste with the relative density of 1.05-1.25 at 70-80 ℃ to obtain the first active component of each traditional Chinese medicine;
Step three, putting the second equal part of each traditional Chinese medicine into an extraction tank, soaking for 12 hours by using 12 times of water, keeping boiling for 1-2 hours at 100 ℃, extracting for 2 times, adding 12 times of water by weight of the total weight of the medicinal materials every time, combining the extracting solutions, filtering, concentrating the filtrate under reduced pressure to obtain clear paste with the relative density of 1.10-1.20 at 70-80 ℃, cooling, adding 4 times of ethanol, fully stirring, standing and refrigerating for 12-24 hours, filtering, recovering the ethanol from the filtrate, concentrating the filtrate under reduced pressure to obtain extract with the relative density of 1.15-1.30 at 70-80 ℃, and obtaining the second active component of each traditional Chinese medicine;
step four, carrying out reflux extraction on the third equal part of each traditional Chinese medicine for 2 times by using 40-80% ethanol, wherein the dosage of the ethanol is 4-10 times of that of the medicinal materials each time, the extraction time is 1-2 hours, combining the extracting solutions, filtering, recovering the ethanol from the filtrate, and concentrating the filtrate under reduced pressure to obtain an extract with the relative density of 1.20-1.35 at the temperature of 60-80 ℃, so as to obtain the third active ingredient of each traditional Chinese medicine;
step five, respectively taking the active ingredients of the first part, the second part and the third part, mixing and stirring 10 parts of apocynum venetum extract, 8 parts of rauwolfia extract, 8 parts of eucommia ulmoides extract, 14 parts of selfheal extract, 16 parts of astragalus membranaceus extract, 12 parts of kudzu root extract, 8 parts of scutellaria baicalensis extract, 10 parts of moutan bark extract, 10 parts of ginkgo leaf extract, 10 parts of gynostemma pentaphylla extract and 12 parts of salvia miltiorrhiza extract uniformly, adding 6 parts of soybean oligopeptide powder, 3 parts of fructus cannabis oligopeptide powder, 8 parts of hesperidin and 3 parts of earthworm powder, mixing and stirring uniformly to obtain mixed powder;
And sixthly, mixing the mixed powder obtained in the fifth step with a medically acceptable carrier to prepare various common preparations, namely tablets, granules, capsules, oral liquid and syrup.
Example 3
A preparation method of a traditional Chinese medicine composition for controlling hypertension comprises the following steps:
step one, after the traditional Chinese medicine raw materials of apocynum venetum, rauvolfia verticillata, eucommia ulmoides, selfheal, astragalus mongholicus, radix puerariae, scutellaria baicalensis, cortex moutan radicis, ginkgo leaves, gynostemma pentaphylla and salvia miltiorrhiza are inspected to be qualified, and each traditional Chinese medicine is independently divided into three equal parts;
Step two, putting the first part of each traditional Chinese medicine into an extraction tank, soaking for 12 hours by using 12 times of water, keeping boiling for 1-2 hours at 100 ℃, extracting for 2 times, adding 12 times of water amount corresponding to the total weight of the medicinal materials each time, combining the extracting solutions, filtering, and concentrating the filtrate under reduced pressure to obtain clear paste with the relative density of 1.05-1.25 at 70-80 ℃ to obtain the first active component of each traditional Chinese medicine;
Step three, putting the second equal part of each traditional Chinese medicine into an extraction tank, soaking for 12 hours by using 12 times of water, keeping boiling for 1-2 hours at 100 ℃, extracting for 2 times, adding 12 times of water by weight of the total weight of the medicinal materials every time, combining the extracting solutions, filtering, concentrating the filtrate under reduced pressure to obtain clear paste with the relative density of 1.10-1.20 at 70-80 ℃, cooling, adding 4 times of ethanol, fully stirring, standing and refrigerating for 12-24 hours, filtering, recovering the ethanol from the filtrate, concentrating the filtrate under reduced pressure to obtain extract with the relative density of 1.15-1.30 at 70-80 ℃, and obtaining the second active component of each traditional Chinese medicine;
step four, carrying out reflux extraction on the third equal part of each traditional Chinese medicine for 2 times by using 40-80% ethanol, wherein the dosage of the ethanol is 4-10 times of that of the medicinal materials each time, the extraction time is 1-2 hours, combining the extracting solutions, filtering, recovering the ethanol from the filtrate, and concentrating the filtrate under reduced pressure to obtain an extract with the relative density of 1.20-1.35 at the temperature of 60-80 ℃, so as to obtain the third active ingredient of each traditional Chinese medicine;
step five, respectively taking the active ingredients of the first part, the second part and the third part, mixing and stirring 8 parts of apocynum venetum extract, 7 parts of rauwolfia extract, 10 parts of eucommia ulmoides extract, 13 parts of selfheal extract, 15 parts of astragalus membranaceus extract, 10 parts of kudzu root extract, 11 parts of scutellaria baicalensis extract, 8 parts of moutan bark extract, 11 parts of ginkgo leaf extract, 10 parts of gynostemma pentaphylla extract and 10 parts of salvia miltiorrhiza extract uniformly, adding 8 parts of soybean oligopeptide powder, 2 parts of fructus cannabis oligopeptide powder, 8 parts of hesperidin and 5 parts of earthworm powder, mixing and stirring uniformly to obtain mixed powder;
And sixthly, mixing the mixed powder obtained in the fifth step with a medically acceptable carrier to prepare various common preparations, namely tablets, granules, capsules, oral liquid and syrup.
Claims (3)
1. a pure traditional Chinese medicine composition for controlling hypertension is characterized in that: the composite material comprises the following raw materials in parts by weight: 6-12 parts of soybean oligopeptide powder, 1-3 parts of fructus cannabis oligopeptide powder, 6-8 parts of hesperidin, 3-6 parts of earthworm powder, 6-10 parts of apocynum venetum extract, 6-8 parts of rauwolfia extract, 8-12 parts of eucommia ulmoides extract, 8-14 parts of selfheal extract, 10-16 parts of astragalus membranaceus extract, 8-12 parts of radix puerariae extract, 8-12 parts of scutellaria baicalensis extract, 6-10 parts of moutan bark extract, 10-12 parts of folium ginkgo extract, 10-12 parts of gynostemma pentaphylla extract and 6-12 parts of salvia miltiorrhiza extract.
2. the method for preparing a pure herbal composition for managing hypertension according to claim 1, wherein the pure herbal composition comprises: step two, putting the first part of each traditional Chinese medicine into an extraction tank, soaking the first part in 12 times of water for 12 hours, keeping boiling at 100 ℃ for 1-2 hours, extracting for 2 times, adding 12 times of water by the total weight of the medicinal materials every time, combining the extracting solutions, filtering, and concentrating the filtrate under reduced pressure to obtain clear paste with the relative density of 1.05-1.25 at 70-80 ℃ to obtain the first active component of each traditional Chinese medicine;
Step three, putting the second equal part of each traditional Chinese medicine into an extraction tank, soaking for 12 hours by using 12 times of water, keeping boiling for 1-2 hours at 100 ℃, extracting for 2 times, adding 12 times of water by weight of the total weight of the medicinal materials every time, combining the extracting solutions, filtering, concentrating the filtrate under reduced pressure to obtain clear paste with the relative density of 1.10-1.20 at 70-80 ℃, cooling, adding 4 times of ethanol, fully stirring, standing and refrigerating for 12-24 hours, filtering, recovering the ethanol from the filtrate, concentrating the filtrate under reduced pressure to obtain extract with the relative density of 1.15-1.30 at 70-80 ℃, and obtaining the second active component of each traditional Chinese medicine; step four, carrying out reflux extraction on the third equal part of each traditional Chinese medicine for 2 times by using 40-80% ethanol, wherein the dosage of the ethanol is 4-10 times of that of the medicinal materials each time, the extraction time is 1-2 hours, combining the extracting solutions, filtering, recovering the ethanol from the filtrate, and concentrating the filtrate under reduced pressure to obtain an extract with the relative density of 1.20-1.35 at the temperature of 60-80 ℃, so as to obtain the third active ingredient of each traditional Chinese medicine; step five, respectively taking the active ingredients of the first, second and third parts in equal parts, mixing and stirring 6-10 parts of apocynum venetum extract, 6-8 parts of rauwolfia extract, 8-12 parts of eucommia ulmoides extract, 8-14 parts of selfheal extract, 10-16 parts of astragalus extract, 8-12 parts of kudzu root extract, 8-12 parts of scutellaria baicalensis extract, 6-10 parts of moutan bark extract, 10-12 parts of ginkgo leaf extract, 10-12 parts of gynostemma pentaphylla extract and 6-12 parts of salvia miltiorrhiza extract uniformly, adding 6-12 parts of soybean oligopeptide powder, 1-3 parts of fructus cannabis oligopeptide powder, 6-8 parts of hesperidin and 3-6 parts of earthworm powder, mixing and stirring uniformly to obtain mixed powder; and sixthly, mixing the mixed powder obtained in the fifth step with a medically acceptable carrier to prepare various common preparations, namely tablets, granules, capsules, oral liquid and syrup.
3. the method for preparing a pure herbal composition for managing hypertension according to claim 2, wherein the pure herbal composition comprises: the medically acceptable carriers are: diluent, wetting agent and adhesive, disintegrating agent, lubricant, cosolvent, corrective and preservative.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910767024.2A CN110538311A (en) | 2019-08-20 | 2019-08-20 | Pure traditional Chinese medicine composition for controlling hypertension and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910767024.2A CN110538311A (en) | 2019-08-20 | 2019-08-20 | Pure traditional Chinese medicine composition for controlling hypertension and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110538311A true CN110538311A (en) | 2019-12-06 |
Family
ID=68711656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910767024.2A Withdrawn CN110538311A (en) | 2019-08-20 | 2019-08-20 | Pure traditional Chinese medicine composition for controlling hypertension and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110538311A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111053823A (en) * | 2020-01-20 | 2020-04-24 | 洪金盛 | A Chinese medicinal composition for regulating hypertension, and its preparation method |
| CN113812552A (en) * | 2021-09-01 | 2021-12-21 | 江南大学 | Total nutrient solid beverage with atherosclerosis preventing function |
-
2019
- 2019-08-20 CN CN201910767024.2A patent/CN110538311A/en not_active Withdrawn
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111053823A (en) * | 2020-01-20 | 2020-04-24 | 洪金盛 | A Chinese medicinal composition for regulating hypertension, and its preparation method |
| CN113812552A (en) * | 2021-09-01 | 2021-12-21 | 江南大学 | Total nutrient solid beverage with atherosclerosis preventing function |
| CN113812552B (en) * | 2021-09-01 | 2023-12-26 | 江南大学 | Total nutrient solid beverage |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7234931B2 (en) | Functional food composition having effects of relieving alcohol-induced hangover symptoms and improving liver function | |
| CN111919934A (en) | Safflower Suxin tea for reducing high blood pressure, high blood sugar and protecting cardiovascular and preparation method thereof | |
| CN110538311A (en) | Pure traditional Chinese medicine composition for controlling hypertension and preparation method thereof | |
| CN104524146A (en) | Traditional Chinese medicine composition for prevention and adjuvant treatment of hypertensive, hyperlipidemia and hyperglycemia and application of traditional Chinese medicine composition | |
| WO2018202107A1 (en) | Pharmaceutical composition for treating hyperlipidemia and atherosclerosis | |
| CN102940730A (en) | Traditional Chinese medicine for treating hypertension | |
| CN101172155A (en) | Novel dosage forms of pulse-activating gallbladder warming soup and method of preparing the same | |
| CN112970992A (en) | Solid beverage suitable for diabetes patients and preparation method thereof | |
| CN106109521A (en) | A kind of Radix Notoginseng oral liquid | |
| CN111135235A (en) | A composition for preventing and relieving acute alcoholism or alcoholic intoxication | |
| CN105687788A (en) | Pharmaceutical composition capable of softening blood vessels and application thereof | |
| KR102282839B1 (en) | Composition for relieving or improving hangover | |
| KR20140010831A (en) | The improved composition for relieving hangovers and protecting a liver | |
| CN106106901A (en) | Health preserving diet tea | |
| CN112402569A (en) | Anti-fatigue health product and preparation method thereof | |
| CN107029124B (en) | Traditional Chinese medicine composition for treating primary hypertension and preparation method thereof | |
| CN105902867B (en) | A herbal composition for reducing hypertension, hyperglycemia and hyperlipidemia, and its preparation method | |
| CN104857121A (en) | Drug combination for curing hyperlipidemia and application thereof | |
| CN117244021B (en) | A Chinese medicinal composition extract for reducing blood sugar, blood lipid, blood pressure and uric acid, and its preparation method | |
| CN109007182A (en) | A kind of Suaeda salsa blood pressure depressing health tea and health protection tea drink and tea bag | |
| CN109105579A (en) | Fire-toxin releasing herb tea | |
| CN109172694A (en) | Blood-pressure decreasing tea and its preparation method and application method | |
| CN114712466B (en) | Medicine with weight-reducing and beautifying effects and preparation method thereof | |
| CN116983359B (en) | Pharmaceutical composition for treating diabetes complicated with coronary heart disease stable angina pectoris | |
| CN113229498A (en) | Medicinal and edible composition formula conducive to blood pressure reduction and preparation process thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20191206 |